Patent US5602098A successfully refreshed from Google Patents.
US5602098A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibition of farnesyltransferase
Assignee: University of Pittsburgh
•
Filing: 1993-05-18
•
Granted: 1997-02-11
•
Expires: 2013-05-18
Abstract
Abstract Peptidomimetics of the formula C-AMBA-X where C is cysteine, X is, for example, methionine or phenylalanine and AMBA is a hydrophobic spacer, notably 3-aminomethylbenzoic acid. These compounds are effective inhibitors of p21 ras farnesyltransferase. Other modifications including alternative spacers for AMBA, and replacement of the A1A2X component of known CA1A2X tetrapeptides by a non-peptide aryl or heterocyclic component are also disclosed as are various phosphonylated and arylated derivatives of peptides and peptidomimetics. Pro-drugs made by functionalizing terminal amino and carboxylic acid groups of peptides and peptidomimetics are also disclosed. Such functionalized derivatives demonstrate increased cell uptake. Other structural modifications are also referred to.
Inventors
- 👤 Said Sebti
- 👤 Andrew Hamilton
- 👤 Churl M. Seong
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:52
CPC Classifications
C; C07; C07C; C07C323/00; C07C323/23; C07C323/24; C07C323/25; C07C323/50; C07C323/51; C07C323/57; C07C323/58; C07C323/59; C07C323/60; C07C329/00; C07C329/02; C07C329/04; C07C329/06; C07D; C07D207/00; C07D207/02; C07D207/30; C07D207/34; C07D215/00; C07D215/02; C07D215/16; C07D215/38; C07D217/00; C07D217/22; C07D263/00; C07D263/02; C07D263/30; C07D263/34; C07D263/48; C07D277/00; C07D277/02; C07D277/20; C07D277/32; C07D277/38; C07D307/00; C07D307/02; C07D307/34; C07D307/56; C07D307/66; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/5437; C07K14/575; C07K14/61; C07K5/00; C07K5/04; C07K5/10; C07K5/1002; C07K5/1005; C07K5/1013; C07K5/1016; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
44 words
A peptidomimetic represented by the formula: C-β-X wherein C is a cysteinyl moiety; X is an amino acid; and β is a residue of ortho-, meta- or para- aminobenzoic acid, or β is a residue of an aminoalkylbenzoic acid; and pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
44 words
A peptidomimetic represented by the formula: C-β-X wherein C is a cysteinyl moiety; X is an amino acid; and β is a residue of ortho-, meta- or para- aminobenzoic acid, or β is a residue of an aminoalkylbenzoic acid; and pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
26 words
A peptidomimetic according to claim 1 wherein C is a cysteinyl moiety, β is the residue of an aminobenzoic acid, and X is an amino acid.
Claim 4
Dependent Claim
12 words
A peptidomimetic according to claim 2 wherein X is methionine or phenylalanine.
Claim 5
Dependent Claim
23 words
A peptidomimetic according to claim 1 wherein C is a cysteinyl moiety, β is the residue of 3-aminomethylbenzoic acid, and X is methionine.
Claim 6
Dependent Claim
23 words
A peptidomimetic according to claim 1 wherein C is a cysteinyl moiety, β is the residue of 4-aminomethylbenzoic acid, and X is methionine.
Claim 7
Dependent Claim
34 words
A prodrug of the peptidomimetic of claim 1 wherein both the α-amino and the sulfhydryl groups of said cysteinyl moiety bear a benzyloxycarbonyl substituent, and the C-terminal carboxyl group of said peptidomimetic is esterified.
Claim 8
Dependent Claim
17 words
A prodrug according to claim 6 wherein said C-terminal carboxyl group is esterified as a methyl ester.
Claim 9
Dependent Claim
23 words
A prodrug according to claim 7 of the following structure: ##STR10## wherein R represents the side chain of a naturally occurring α-amino acid.
Claim 10
Dependent Claim
27 words
A pharmaceuticals composition comprising a peptidomimetic according to any of claims 1-5 or a prodrug according to any of claims 6-8, together with a pharmaceutically acceptable carrier.
Claim 11
Independent Claim
38 words
A method of inhibiting farnesyltransferase in a mammal comprising administering to said mammal a peptidomimetic according to any of claims 1-5 or a prodrug according to any of claims 6-8 in an amount effective to inhibit said farnesyltransferase.
References Cited (Backward Citations)
EP0203587A2
Cited
WO1991016340A1
Cited
US5141851A
Cited
US5043268A
Cited
EP0456180A1
Cited
EP0461869A2
Cited
WO1992018465A1
Cited
EP0512865A2
Cited
CA2072033A1
Cited
EP0520823A2
Cited
EP0523873A1
Cited
EP0528486A2
Cited
EP0534546A1
Cited
EP0535730A2
Cited
US5238922A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-02-11 | 2000-08-12 | 2001-02-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-02-11 | 2004-08-12 | 2005-02-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-02-11 | 2008-08-12 | 2009-02-11 | $7700.00 | Window Closed / Lapsed |